DMAC
DiaMedica Therapeutics Inc (DMAC)
Healthcare • NASDAQ • $6.32-3.22%
- Symbol
- DMAC
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $6.32
- Daily Change
- -3.22%
- Market Cap
- $340.54M
- Trailing P/E
- N/A
- Forward P/E
- -7.52
- 52W High
- $10.42
- 52W Low
- $3.48
- Analyst Target
- $15.50
- Dividend Yield
- N/A
- Beta
- 0.99
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in…
Company websiteResearch DMAC on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.